An observational study in Atheromatous, sponsored by Hôpital NOVO. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-09.
Sponsored by Hôpital NOVO · Observational
Among 10 studies in Plaque, Atherosclerotic with a site in France — 5 open to participants now, 7 under way, 1 of them phase 3. Plaque, Atherosclerotic · France.
Among the 10 studies in Plaque, Atherosclerotic with a site in France, this one is the only one that started in 2014, is one of 4 observational ones, and was the 3rd registered.
105 studies on the registry are indexed under Plaque, Atherosclerotic; 27 are open to participants now.
Browse Plaque, Atherosclerotic studies →5 of the 10 studies in Plaque, Atherosclerotic with a site in France are open now. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Assistance Publique Hopitaux De Marseille · Sites in France
Ages 45–80
Elsan · Sites in France
Ages 40–80
GCS Ramsay Santé pour l'Enseignement et la Recherche · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 16 Plaque, Atherosclerotic studies recruiting now, 7 (44%) set no upper age limit and 4 (25%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 146 across 50 observational studies indexed under Plaque, Atherosclerotic.
Median enrollment 385 across the 6 interventional studies, 100 across the 4 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 9 most frequent:
Hôpital NOVO is the lead sponsor of 70 studies on the registry; 19 are open to participants now.
Hôpital NOVO has 1 study filed under Plaque, Atherosclerotic — fewer than ten, so there is no comparison to draw.
2 of the studies in Plaque, Atherosclerotic with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06804707Hospices Civils de LyonCarotid Plaque Characterization Using Innovative Ultrasound Techniques | 2027-02-13 |
| NCT06226844Centre Hospitalier Universitaire de NīmesCan the BeatMove Device Help Patients With Obliterative Arterial Disease of the Lower Limbs? | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Plaque, Atherosclerotic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Endarteriectomy is considered as the first line treatment of femoral bifurcation atheromatous lesions. Eversion technique, similar to that used for carotid bifurcation, is safe and possible for the majority of the femoral tripod lesions. The major advantage of the eversion technique is the absence of prosthetic material to be performed. However, its use has been scarcely evaluated in the literature to date. This work aims at evaluating the long term safety and the efficacy of eversion femoral technique. Surgical technique was thoroughly described and participants were followed up for two years by serial clinical and doppler US examination.
Femoral bifurcation lesions is one of the most frequent lesion encountered in lower limb atheromatous occlusive disease. Current treatment options consists in femoral endarteriectomy or bypass. More recently, endovascular treatment of femoral tripod lesions has been reported. Inguinal area is prone to postoperative infection in up to 20% of the cases. Hence, the use of synthetic graft puts the participants at risk of dramatic consequences in case of postoperative infection. Besides, long term data are still required to validate the use of endovascular device in this very "surgical" area. The use of the eversion technique is possible in the majority of the lesions and offer the major advantage of open surgery in terms of durability, without the use of synthetic material in case of postoperative infection.
The investigators herein report the detailed technique, tips and variations of the eversion technique as well as the clinical follow up in terms of clinical benefit according to Rutherford classification and restenosis evaluated by serial doppler US.
Register including all patients who have been treated with the femoral eversion technique.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The purpose of this database is to compile the data of patients followed at the René Dubos Hospital Center with symptomatic lower extremity arterial disease (AOMI) (Rutherford 2 to 5) who were operated on by the femoral tripod eversion technique. The database will include data on the operation, possible complications, clinical course of patients and medical and surgical follow-up.
Clinical follow-up
Observation of the clinical and life-threatening status of the participants twelve months after the operation. From a general point of view observation of clinical improvement according to Rutherford classification.
Time frame: One year.
Clinical complications
Clinical follow-up and echo-Doppler was obtained at one month, six months and twelve months.
Time frame: At one month, six months and twelve months.
Plan to share: No
No publications or documents are linked to this record.
Ran from Jun 2014 to primary completion in Apr 2016, 22 months.
Of 31 observational studies under Plaque, Atherosclerotic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 105. This study's 22 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hôpital NOVO